Once-Daily OROS® Methylphenidate Is Safe and Well Tolerated in Adolescents With Attention-Deficit/Hyperactivity Disorder

Authors

James J. McGough
Keith McBurnett
Oscar Bukstein
Timothy E. Wilens
Laurence Greenhill
Marc Lerner
Mark Stein
John C. Duby, Wright State UniversityFollow

Document Type

Article

Publication Date

6-2006

Find in a Library

Catalog Record

Abstract

This 8-week, open-label extension of a double-blind study reports on safety data for 171 adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily OROS^® methylphenidate (MPH) (18–72 mg/day). Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events. The incidence of adverse events was not related to dose. OROS MPH was safe and well tolerated at doses up to 72 mg/day.

Repository Citation

McGough, J. J., McBurnett, K., Bukstein, O., Wilens, T. E., Greenhill, L., Lerner, M., Stein, M., & Duby, J. C. (2006). Once-Daily OROS® Methylphenidate Is Safe and Well Tolerated in Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 16 (3), 351-356.
https://corescholar.libraries.wright.edu/pediatrics/171

DOI

10.1089/cap.2006.16.351